Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
Adlai Nortye Ltd. (ANL)
Company Research
Source: GlobeNewswire
SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private placement expenses. The oversubscribed transaction includes participation from both new and existing institutional investors. New investors include Soleus Capital, Perceptive Advisors, ADAR1 Capital Management, MPM BioImpact, Octagon Capital, Eventide Asset Management and Kalehua Capital, DAFNA Capital Management, etc., with additional participation from existing investors including Cormorant Asset Management, Columbia Threadneedle Investments, Balyasny Asset Management, Casdin Capital and Squad
Show less
Read more
Impact Snapshot
Event Time:
ANL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANL alerts
High impacting Adlai Nortye Ltd. news events
Weekly update
A roundup of the hottest topics
ANL
News
- Adlai Nortye (ANL) had its "buy" rating reaffirmed by HC Wainwright.MarketBeat
- Adlai Nortye (ANL) is now covered by Leerink Partners. They set an "outperform" rating and a $23.00 price target on the stock.MarketBeat
- Adlai Nortye (ANL) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ANL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to "hold".MarketBeat
- Adlai Nortye (NASDAQ:ANL) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.MarketBeat
- Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS MutationsGlobeNewswire
ANL
Sec Filings
- 4/23/26 - Form F-3/A
- 4/16/26 - Form 6-K
- 4/10/26 - Form 20-F
- ANL's page on the SEC website